KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Construction and application of an ERAS-based nursing pathway for postoperative pain management in brain tumor patients. PMID 41618043 · J Neurooncol · 2026-Jan-30 The study is a randomized trial in oncology (brain tumor surgery) with human subjects and reports original results, but it does not meet key eligibility criteria. It is not a Phase III/IIIb or definitive Phase II/III trial (phase is not specified). The intervention is a non-drug nursing pathway (ERAS-based), not a drug-containing intervention. The primary endpoints are pain scores, analgesic consumption, recovery metrics, and satisfaction; none are time-to-event efficacy endpoints like OS, PFS, DFS, EFS, RFS, or TTP, and there is no mention of Kaplan-Meier analysis or hazard ratios.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. PMID 41617393 · J Immunother Cancer · 2026-Jan-30 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial. PMID 41617358 · RMD Open · 2026-Jan-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of Mobilization Facilitated by Wearable Device Enhanced Patient Monitoring/Electrophysiology Pod-Based Feedback on Postoperative Complications Following Colorectal Cancer Surgery: Randomized Controlled Trial. PMID 41616372 · JMIR Mhealth Uhealth · 2026-Jan-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
PD-L1 subpopulations of metastatic urothelial carcinoma demonstrate heterogeneity to chemotherapy: an integrated analysis of digitized trial results. PMID 41615520 · Cancer Metastasis Rev · 2026-Jan-30 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A pragmatic trial with an optimized dose of rifampicin and moxifloxacin for the treatment of drug-susceptible pulmonary tuberculosis: a study protocol for open-label, randomized phase III trial (OptiRiMoxTB). PMID 41612490 · Trials · 2026-Jan-30 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Exploring clusters based on ultrasound-detected inflammation in patients with psoriatic arthritis: a post-hoc analysis from the ULTIMATE trial. PMID 41612350 · BMC Musculoskelet Disord · 2026-Jan-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium. PMID 41611967 · Eur J Hum Genet · 2026-Jan-29 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial. PMID 41609025 · Haematologica · 2026-Jan-29 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion. PMID 41604638 · N Engl J Med · 2026-Jan-29 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. PMID 41211918 · N Engl J Med · 2026-Jan-29 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Major Advances in Gynecologic Oncology in 2025: Systematic Review and Synthesis of Conference and Published Evidence. PMID 41751194 · Biomedicines · 2026-Jan-28 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Evaluating the impact of age on prostate cancer overdiagnosis using long-term follow-up from a randomised trial. PMID 41646805 · medRxiv · 2026-Jan-28 The study is a randomized trial in oncology (prostate cancer) with long-term follow-up, but it does not involve a drug-containing intervention (PSA screening is diagnostic) and does not have a time-to-event efficacy endpoint (it measures overdiagnosis incidence, not survival outcomes). Therefore, it does not meet the eligibility criteria for inclusion in the Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluating the impact of financial navigation on financial catastrophe and distress for cancer care: a randomized control trial-COST-FIN. PMID 41606671 · Trials · 2026-Jan-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Design, development, and evaluation of a web-based consultation system for birth after cesarean: a mixed-method study protocol. PMID 41606529 · BMC Pregnancy Childbirth · 2026-Jan-28 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Adherence to oral endocrine therapy by menopausal status: post hoc insights from a remote monitoring randomized trial. PMID 41605963 · NPJ Breast Cancer · 2026-Jan-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Family-Centered Advance Care Planning in Patients With Breast Cancer: A Randomized Controlled Trial in China. PMID 41604160 · Omega (Westport) · 2026-Jan-28 The record describes a randomized trial in oncology patients, but it is ineligible because it is not a drug intervention trial, does not report time-to-event efficacy endpoints, and the phase is not established as definitive Phase III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination. PMID 41604000 · J Neurooncol · 2026-Jan-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Study protocol of a pilot randomised controlled trial examining massed culturally adapted Problem Management Plus (PM +) in South Africa. PMID 41593712 · Pilot Feasibility Stud · 2026-Jan-27 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: a prospective, single-arm, phase 2 study. PMID 41593669 · BMC Med · 2026-Jan-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trial. PMID 41593108 · NPJ Breast Cancer · 2026-Jan-27 The record describes a randomized oncology trial with human patients and time-to-event endpoints (iDFS, OS). However, it is excluded because it lacks a drug-containing intervention; it compares surgical procedures only.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized controlled trial. PMID 41591582 · Cancer Immunol Immunother · 2026-Jan-27 The record is an extended follow-up of a randomized controlled trial with an oncology endpoint (RFS) and a drug/cell-based intervention. However, the phase of the original trial is not explicitly stated as Phase III/IIIb or Phase II/III in the title, abstract, or metadata. It is described as a 'randomized controlled trial' but the specific trial phase is not provided, preventing definitive inclusion based on the required phase criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of anti-LAG-3 IBI110 in combination with sintilimab and chemotherapy for advanced squamous non-small cell lung cancer: a randomized phase II study. PMID 41591537 · Cancer Immunol Immunother · 2026-Jan-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Potent P2Y12 Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI: The NEO-MINDSET Substudy. PMID 41384891 · J Am Coll Cardiol · 2026-Jan-27 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The cost-effectiveness of using vilobelimab with immunomodulators to treat severely ill mechanically ventilated patients with COVID-19: A subgroup analysis of the PANAMO study. PMID 40638782 · Am J Health Syst Pharm · 2026-Jan-27 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Camrelizumab Combination Therapy in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. PMID 41589607 · Am J Clin Oncol · 2026-Jan-26 The record is a systematic review and meta-analysis, which is an excluded report type. It does not meet the criterion for an 'original result' of a single Phase III/IIIb or Phase II/III randomized trial. While it discusses Phase III trials in the conclusion, the included studies' phases are not explicitly established as definitive Phase III/IIIb or Phase II/III in the provided abstract.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Follow-up intensity after colorectal cancer surgery in patients aged ≤ 50, 50-70 and > 70 years - an analysis within the COLOFOL randomised clinical trial. PMID 41586910 · Int J Colorectal Dis · 2026-Jan-26 The study is a randomized trial of follow-up intensity after colorectal cancer surgery. It reports 5-year mortality and recurrence risks (risk differences), not time-to-event endpoints (OS, PFS, DFS, etc.) with Kaplan-Meier or HR. It lacks a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study. PMID 41681846 · Cancers (Basel) · 2026-Jan-25 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
B
仅广召回影子组 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
[Efficacy and safety of triptorelin acetate microspheres for injection versus triptorelin acetate for injection in Chinese patients with endometriosis: a multicenter, randomized, double-blind, phase Ⅲ non-inferiority clinical trial]. PMID 41611266 · Zhonghua Fu Chan Ke Za Zhi · 2026-Jan-25 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Stroma-driven intertumoral and intratumoral heterogeneity of PD-L1 expression in cholangiocarcinoma: Implications for biomarker development and prognostic evaluation. PMID 41587324 · Hepatology · 2026-Jan-24 The record describes a retrospective biomarker and prognostic analysis of intrahepatic cholangiocarcinoma, not the formal results of a randomized clinical trial. It lacks all key trial elements: randomization, a defined phase, a drug-containing intervention arm, and a primary time-to-event efficacy endpoint. The discussion of immune checkpoint inhibitors is contextual, not as an evaluated intervention in this study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Drug re-purposing to improve outcomes in the management of prostate cancer - aims, outcome measures and design of current phase III trials. PMID 41580831 · BMC Pharmacol Toxicol · 2026-Jan-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial. PMID 41544643 · Lancet · 2026-Jan-24 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H L S B
旧组与严格 v3 交集 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Evaluating the use of hierarchical composite endpoints in pediatric cancer supportive care clinical trials: Illustrative examples from two multi-center phase-III randomized clinical trials. PMID 41659071 · medRxiv · 2026-Jan-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Development and pilot testing of AYA-RISE, a risk information and screening education intervention for adolescents and young adults with cancer risk syndromes. PMID 41575674 · Fam Cancer · 2026-Jan-23 The record describes a pilot study for a non-drug educational intervention, with no randomized trial results, no drug intervention, and no time-to-event endpoint reported.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prognostic Factors for Overall Survival in the VESPER Trial: Basal Molecular Subtype Is a Relevant Key Factor. PMID 41577609 · Eur Urol Oncol · 2026-Jan-22 The record is an original secondary analysis (prognostic factor study) from the VESPER trial, not the primary efficacy report. The abstract does not explicitly state the trial phase (Phase III/IIIb or Phase II/III), and the deterministic review notes phase evidence is unclear. While it meets criteria for oncology, human, randomized, drug intervention, and time-to-event endpoint, it fails the 'phase3_or_definitive' criterion and is not the primary result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effectiveness and cost-effectiveness of ozone treatment in patients with paraesthesia (numbness, tingling) secondary to chemotherapy-induced peripheral neuropathy: randomized, triple-blind clinical trial (OzoParQT). PMID 41572235 · BMC Cancer · 2026-Jan-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of a behavioral counseling for adoption and maintenance of a physically active lifestyle on long-term mortality in people with type 2 diabetes: post hoc analysis of the Italian Diabetes and Exercise Study_2. PMID 41571659 · Nat Commun · 2026-Jan-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Jiedu Xiaozhen Granules for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Mediated Skin Toxicity: Protocol for a Randomized Controlled Trial. PMID 41570298 · JMIR Res Protoc · 2026-Jan-22 The record is a protocol for an ongoing randomized controlled trial. It does not contain formal results from a completed Phase III/IIIb or Phase II/III randomized trial with a primary time-to-event efficacy endpoint. The phase is unclear, and it is explicitly not a result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The efficacy of complex decongestive therapy in the treatment of lymphedema associated with endometrial and cervical cancer: evaluation of sensation and balance. PMID 41569453 · Support Care Cancer · 2026-Jan-22 The study is an oncology-related randomized trial in humans, but it lacks a drug-containing intervention, is not Phase III/IIIb or Phase II/III, and does not have a time-to-event efficacy endpoint. It evaluates a physical therapy intervention for lymphedema symptoms.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluating the Impact of Financial Navigation on Financial Catastrophe and Distress for Cancer Care: A Randomized Control Trial- COST-FIN. PMID 41646304 · Res Sq · 2026-Jan-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
First-in-class HIF-2α therapy in genitourinary oncology: Belzutifan from von Hippel-Lindau disease to advanced renal cell carcinoma. PMID 41569310 · Cancer Chemother Pharmacol · 2026-Jan-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Ferric citrate for iron deficiency anemia in non-dialysis dependent chronic kidney disease: a randomized phase III study. PMID 41558722 · Kidney Res Clin Pract · 2026-Jan-21 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Correction: Wang et al. Immune Persistence Following a Single Dose of Varicella Vaccine: 5-Year and 8-Year Follow-Up of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Vaccines 2025, 13, 1024. PMID 41601025 · Vaccines (Basel) · 2026-Jan-20 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Menin Inhibition in Acute Myeloid Leukemia: Pathobiology, Progress and Promise. PMID 41595753 · Biomedicines · 2026-Jan-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized Trial. PMID 41565552 · Eur Urol Oncol · 2026-Jan-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Long-acting HIV pre-exposure prophylaxis integrated with community-based sexual and reproductive health services in South Africa (LAPIS): study protocol for a hybrid (1a) cluster randomised controlled phase 3B trial of effectiveness and implementation. PMID 41559582 · BMC Public Health · 2026-Jan-20 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effect of Lung Cancer Screening, Smoking Cessation, and Cessation Smartphone App to Health-Related Quality of Life Among Heavy Smokers: Randomized Controlled Trial. PMID 41557895 · J Med Internet Res · 2026-Jan-20 Study is a randomized controlled trial in the context of lung cancer screening, but it evaluates health-related quality of life as an exploratory endpoint, not a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Additionally, the intervention is a smoking cessation smartphone app, not a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term survival outcomes of laparoscopic total gastrectomy vs open total gastrectomy in patients with clinical stage I gastric cancer the CLASS02 randomized clinical trial. PMID 41556169 · Int J Surg · 2026-Jan-20 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Ligelizumab in Individuals With Confirmed Peanut Allergy. PMID 41555809 · Allergy · 2026-Jan-20 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Paclitaxel-Coated Balloon for Treating In-Stent Restenosis in Racial and Ethnic Minority Patients: A Subanalysis From the AGENT IDE Trial. PMID 41553096 · J Am Heart Assoc · 2026-Jan-20 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -